GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a statement in response to the World Health Organization’s ...

Preclinical Studies Demonstrate Durable Protection Against SARS-CoV-2 Variants, Including Omicron XBB.1.5, Driven by T-Cell Responses  ATLANTA, GA - June 9, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.

Data from Two Key Studies Highlight CrossReactivity and BroadSpectrum Immunity of GEO-CM04S1 and GeoVax Multi-Antigen Vaccine ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2024 Earnings Call Transcript March 27, 2025 GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.79. Operator ...

ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases ...

If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative, or please contact the company directly at [email protected]. GeoVax Labs ...

GeoVax announces an offering of 1.7 million shares at a price of $5 per share. GeoVax says it expects approximately $8.5 million in gross proceeds from the offering. Feel unsure about the market ...

GeoVax shares began moving higher last week after the World Health Organization declared a public health emergency in response to an mpox. EF Hutton analyst Jason Kolbert maintains Geovax with a ...

ATLANTA - GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology firm specializing in vaccines and immunotherapies for infectious diseases and cancer, has secured a substantial contract from the Biomedical ...